CHEERS-AI Economic Evaluation

By João L. Carapinha

November 5, 2024

NICE (National Institute for Health and Care Excellence) introduces CHEERS-AI! It’s a new reporting standard optimized for health economic evaluations of AI technologies in healthcare. The EU funded CHEERS-AI as part of the Next Generation Health Technology Assessment (HTx) project. Its primary aim is to enhance the transparency and quality of cost-effectiveness studies specifically tailored for AI-enabled healthcare interventions.

Purpose and Background

CHEERS-AI seeks to systematically address the challenges facing health economic evaluations of AI interventions. A systematic review has identified several issues, including poor quality input data, author conflicts of interest, lack of transparent reporting, and vague information regarding AI functionality.

Solution: CHEERS-AI economic evaluation

Building on the established CHEERS 2022 standards, CHEERS-AI incorporates the original 28 standards while adding 8 new details for AI-related nuances and 10 AI-specific standards. The extra standards tackle key aspects such as user autonomy, continuous AI learning, and the methodology behind developing the AI component.

Objectives

The primary goal of CHEERS-AI is to ensure transparent and reproducible reporting of AI-specific details in health economic evaluations. This standard will aid healthcare decision-makers in understanding the value of AI-enabled treatments, ultimately facilitating faster access to promising AI technologies for patients.

Endorsement and Integration

ISPOR endorsed CHEERS-AI and is now included in the EQUATOR Network checklist of reporting guidelines. This endorsement ensures integration into best practices for health economic evaluation reporting.

Impact

Refining the quality and transparency of health economic evaluations involving AI technologies is an important objective. In doing so, CHEERS-AI aims to elevate the standards of economic evaluation reporting. This improvement is vital for reimbursement decisions and the broader adoption of AI in healthcare.

In summary, CHEERS-AI represents an advancement in standardizing and enhancing health economic evaluations of AI technologies, thereby supporting improved decision-making in healthcare.

Reference url

Recent Posts

suzetrigine pain management
      

Journavx for Pain Management: Toward Affordability and Access

💊 The jury is out on the pricing for Journavx®

Delve into our review of the recent ICER 2025 report on suzetrigine (Journavx®) to learn about the anticipated value relative to its clinical efficacy, safety profile and potential cost savings in tackling acute pain while addressing the opioid crisis.

Explore how suzetrigine paves the way for a safer, more effective approach to pain management and its implications on healthcare economics.

#SyenzaNews #HealthEconomics #HealthcareInnovation #Journavx

defunding scientific research
      

Defunding Scientific Research: Implications and Misconceptions in Gawande’s Analysis of Harvard Funding Cuts

🚨 What happens when scientific research funding is threatened?

In his thought-provoking article, Atul Gawande highlights the dire implications of proposed federal funding cuts to elite institutions like Harvard. He argues that such actions could devastate not just innovation, but also patient care and public health across the nation.

Explore the complexities of research funding and the potential ripple effects on America’s scientific landscape. Don’t miss out on these critical insights!

#SyenzaNews #HealthcareInnovation #HealthEconomics #MarketAccess

perioperative immunotherapy bladder cancer
       

FDA Approves Perioperative Immunotherapy for Bladder Cancer: A Breakthrough in MIBC Treatment

🚀 Are we witnessing a new era in bladder cancer treatment?

The FDA’s recent approval of durvalumab as the first perioperative immunotherapy for muscle-invasive bladder cancer (MIBC) could revolutionize outcomes for patients facing this formidable diagnosis. With significant improvements in event-free survival and overall survival over standard chemotherapy, this groundbreaking treatment offers new hope 🎉.

Curious about how this could shape the future of cancer care? Dive into the full article to uncover the potential impacts on clinical practice and health economics.

#SyenzaNews #oncology #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.